Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease
Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease
复制标题
DOI：
10.1016/s0006-3223(03)00318-4
复制
发表时间：
2003-08-01
影响因子：
10.6
通讯作者：
Petitto, JM
中科院分区：
文献类型：
--
作者：
Cruess, DG;Evans, DL;Petitto, JM
人类免疫缺陷病毒血清阳性（HIV+）个体患情绪障碍和相关综合症的风险较高。在过去的几十年里，据报道，艾滋病病毒感染者中情绪障碍（包括抑郁症和躁狂症）的发病率有所增加。由于情绪的改变可能会影响生活质量，并可能降低抗逆转录病毒治疗方案的依从性，而抗逆转录病毒治疗方案对于预防疾病进展至关重要，因此识别和有效治疗情绪障碍至关重要。越来越多的数据表明，抗抑郁药和情绪稳定剂以及其他新型药物可能对患有伴随情绪障碍的艾滋病病毒感染者有益。这篇综述重点介绍了相关研究，这些研究检查了艾滋病毒+个体情绪障碍的患病率、影响情绪障碍诊断和精神药理学治疗的艾滋病毒疾病特征，包括与抗逆转录病毒药物的复杂相互作用，以及有关艾滋病毒疾病背景下用于治疗抑郁症和躁狂症的药物疗效的现有证据。 (C) 2003 年生物精神病学协会。
Human immunodeficiency virus seropositive (HIV+) individuals are at a heightened risk of developing mood disorders and related syndromes. Over the past several decades, increased rates of mood disorders, including depression and mania, have been reported among HIV+ individuals. Because alterations in mood may impact on quality of life and perhaps reduce adherence to antiretroviral treatment regimens that are critical for preventing disease progression, recognition and effective treatment of mood disorders is essential. There are accumulating data showing that antidepressants and mood stabilizers, as well as other novel agents, might benefit HIV+ individuals suffering from a concomitant mood disturbance. This review highlights the relevant studies that have examined prevalence rates of mood disorders in HIV+ individuals, characteristics of HIV disease that influence the diagnosis and psychopharmacologic treatment of mood disorders, including complex interactions with antiretroviral medications, as well as the available evidence regarding the efficacy of agents used to treat depression and mania in the context of HIV disease. (C) 2003 Society of Biological Psychiatry.